Spetzler David Baxley, PRES, reported an open-market or private sale at Caris Life Sciences, Inc. involving 84900.000000 shares for an estimated $2149676.49. Reported holdings after the transaction were 1052083.000000 shares. A 10b5-1 reference was not detected in the stored filing text.
Stored Form 4 columns with their raw values
Badges describe filing facts only — not predictions.
Compact filing score computed from stored Form 4 facts. Version v1.
This filing has a modest positive filing-only score. Treat it as a useful flag for review, not as a buy signal.
Form 4 relationship flags and nearby filing context
President
The sales reported on this Form 4 were effected pursuant to a broker-assisted sell-to-cover exercise of fully vested stock options scheduled to expire on September 12, 2026. The shares were sold solel…
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.3200 to $25.3100, inclusive. The reporting person undertakes to p…
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.3200 to $25.3300, inclusive. The reporting person undertakes to p…
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.5550 to $25.1200, inclusive. The reporting person undertakes to p…
Exercise of stock options before their expiration date.
The stock option is fully vested and exercisable.
0 other filings
0 recent txs